Clinical Trial Detail

NCT ID NCT02318901
Title Pembrolizumab and Monoclonal Antibody Therapy in Advanced Cancer
Recruitment Terminated
Gender both
Phase Phase Ib/II
Variant Requirements Yes
Sponsors Western Regional Medical Center

Her2-receptor positive breast cancer

gastroesophageal junction adenocarcinoma

head and neck squamous cell carcinoma

Advanced Solid Tumor

stomach cancer

colorectal cancer


Ado-trastuzumab emtansine + Pembrolizumab

Pembrolizumab + Trastuzumab

Cetuximab + Pembrolizumab

Age Groups: adult

Additional content available in CKB BOOST